Chf results are so amzing yet they failed to reach the specified endpoint. Perfect outcome for a big pharma company that was waiting for results until they made a deal. Imo any big pharma could get these trial results approved on the back of probability of statistical signifigance results and all the secondary endpointsmet.
If Meso applies on its own its a crapshoot.
So we need to partner with less strength that a primary endpoint pass would have given us.
Does not change the reality that Meso owns thepatents and the 12 years to get to this point.
Market cap of the stem cell companies have been kept low to allow big pharma to negotiate great deals and it has worked well for them.
Ita all ready to play out now.
Ceo of Pfizer recently stated that good acquisitions have neverbeen priced higher.
This is the future fellow research comrades
Partnerships vs FDA, page-42
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |